Gapping up
In reaction to strong earnings/guidance: LCI +14.6%, NMBL +10.7%, LTRX +8.6%, GOGL +2%
M&A news: LEI +19.3% (shareholders vote to approve Segundo transaction and related financings)
Select financial related names showing strength: LYG +3.2%, BCS +2.2%, DB +2.1%, BBVA +2%, SAN +1.9%, HSBC+1.1%
Other news:
In reaction to strong earnings/guidance: LCI +14.6%, NMBL +10.7%, LTRX +8.6%, GOGL +2%
M&A news: LEI +19.3% (shareholders vote to approve Segundo transaction and related financings)
Select financial related names showing strength: LYG +3.2%, BCS +2.2%, DB +2.1%, BBVA +2%, SAN +1.9%, HSBC+1.1%
Other news:
- URRE +56.8% (develops energy metals business and acquires its first lithium property in Nevada)
- AEHR +22.8% (announces a development/manufacturing partnership including an investment by Semics in 200K shares of Aehr Test Systems common stock)
- INSY +12.2% (reports that the Phase 3 trial for the Buprenorphine Sublingual Spray met its primary endpoint)
- OSUR +8.6% (receives a contract for up to $16.6 million in total funding from the U.S. Department of Health and Human Services to advance the Company's rapid Zika tests)
- CLVS +7.9% (continued strength after yesterday's FDA approval of NDA for Rucaparib)
- RADA +6.2% (cont strength)
- WNC +6.2% (will replace EnerSys in the S&P SmallCap 600)
- SCYX +5.6% (granted orphan designation by the FDA for its (1,3)-ß-D-glucan synthesis inhibitor for the treatment of invasive Aspergillus infections)
- FIT +2.7% (continued strength after yesterday's FDA approval of NDA for Rucaparib)
- FLO +1.8% (Directors (2) disclosed purchase of 24000 shares, worth total of $365.3K)
- AAN +1.1% (light volume, Director disclosed purchase of 40K shares, worth total of ~$1.01 mln)
- GPRO +1.1% (cont strength on the back of BBY earnings call yesterday)
- VRX +1% (cont strength)
- MOMO +1% (cont strength)
Analyst comments:
- NEWM -2% (downgraded to Sell from Neutral at Citigroup)
- CSIQ -2.7% (downgraded to Equal Weight from Overweight at Barclays)